Follow

NH TherAguix

Euronext Growth Paris (France)

NH TherAguix has developed an innovative nano drug to improve cancer treatment by radiotherapy. Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.

Sector:
HEALTH CARE
>
Biotechnology
News
No available news yet for NH TherAguix
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
ALNHT
FR0013105954
Euronext Growth Paris
France (FR)
Details of share in NH TherAguix with ticker ALNHT
Status
Active
Amount of instruments
Currency
EUR
First trading date
15 Oct 2021
Type
Price
Pre-money
Time
Files
IPO
Cancelled
15.50-18.90 EUR
103.73M EUR
28 Sep - 11 Oct 2021
IPO in NH TherAguix has been cancelled
People
Géraldine Le Duc
CEO
Hervé Brailly
Chairman of the board
Philippe Archinard
Board member
Philippe Boucheron
Board member
Marc Le Bozec
Board member
Yannick Plétan
Board member
Thibaut Roulon
Board member
Célia Hart
Board member
Olivier Tillement
Board member
Company Details
Sector
HEALTH CARE
Website

Address
29 Chemin du Vieux ChĂȘne
Zip code
38240
City/district
Tarmac
Country
France (FR)
Registration number
815 260 278
LEI code
9695007Z8UJ5AFRZQN66
First trade date
15 Oct 2021
Registration date
15 Dec 2015
Short name
NHT

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More